Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

Diabetes, oxidative stress, and antioxidants: A review

Maritim, A. C., Sanders, R. A., & Watkins, J. B. (2003) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.10058 · Cited by 3,167

[41] Measurement of protein thiol groups and glutathione in plasma

Hu, M. (1994) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(94)33044-1 · Cited by 962

Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: Potential implications in intracellular fluorescence detection of superoxide

Zhao, H., Kalivendi, S., Zhang, H., Joseph, J., Nithipatikom, K., Vásquez-Vivar, J., & Kalyanaraman, B. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00142-4 · Cited by 803

Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A

Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 275

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases

Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232

Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma

Nourooz‐Zadeh, J. (1999) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(99)00113-5 · Cited by 225

Enzyme immunoassays of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate using acetylcholinesterase

Pradelles, P., Grassi, J. J., Chabardès, D., & Guiso, N. (1989) · Analytical Chemistry · doi:10.1021/ac00180a014 · Cited by 154

Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity

Cabou, C., Campistron, G., Marsollier, N., Leloup, C., Cruciani‐Guglielmacci, C., Pénicaud, L., Drucker, D. J., Magnan, C., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db08-0121 · Cited by 121

Therapy in the Early Stage: Incretins

Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 114

Effect of four‐week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes

Pavlovic, D. D., Kocić, R., Kocic, G. M., Jevtović, T., Radenković, S., Mikić, D., Stojanović, M., & Djordjević, P. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00089.x · Cited by 113

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407

The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists

Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406

Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling

Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217

Pharmacotherapy of type 2 diabetes: An update and future directions

DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152

The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome

Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study

Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135

The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases

Andreadi, A., Bellia, A., Daniele, N. D., Meloni, M., Lauro, R., Della‐Morte, D., & Lauro, D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.010 · Cited by 136

The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes

Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415743 · Cited by 140

Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress

Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114

Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity

Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 103

Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options

Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 97

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect

Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00962-3 · Cited by 81

Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence

Marino, A., Campanella, C., Barone, R., Bavisotto, C. C., Górska‐Ponikowska, M., Woźniak, M., Carini, F., Cappello, F., D’Anneo, A., Lauricella, M., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.045 · Cited by 78

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases

Giglio, R. V., Sasso, B. L., Agnello, L., Bivona, G., Maniscalco, R., Ligi, D., Mannello, F., & Ciaccio, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113634 · Cited by 72

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study

Castellino, G., Nikolić, D., Magán‐Fernández, A., Malfa, G. A., Chianetta, R., Patti, A. M., Amato, A., Montalto, G., Toth, P. P., Banach, M., et al. (2019) · Nutrients · doi:10.3390/nu11112580 · Cited by 63

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

Zobel, E. H., Ripa, R. S., von Scholten, B. J., Rotbain Curovic, V., Kjaer, A., Hansen, T. W., Rossing, P., & Størling, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-97967-0 · Cited by 59

The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes

Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 63

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58

Oxidative stress in obesity and insulin resistance

Panić, A., Stanimirović, J., Sudar-Milovanovic, E. M., & Isenović, E. R. (2022) · Exploration of Medicine · doi:10.37349/emed.2022.00074 · Cited by 63

Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress

Signorelli, S. S., Volsi, G. L., Pitruzzella, A., Fiore, V., Mangiafico, M., Vanella, L., Parenti, R., Rizzo, M., & Volti, G. L. (2016) · Angiology · doi:10.1177/0003319716638242 · Cited by 57

Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study

Patti, A. M., Nikolić, D., Magán‐Fernández, A., Giglio, R. V., Castellino, G., Chianetta, R., Citarrella, R., Corrado, E., Provenzano, F., Provenzano, V., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.006 · Cited by 58

Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects

Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.27 · Cited by 58

Future perspectives of the pharmacological management of diabetic dyslipidemia

Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 55

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

Giglio, R. V., Nikolić, D., Volti, G. L., Stoian, A. P., Banerjee, Y., Magán‐Fernández, A., Castellino, G., Patti, A. M., Chianetta, R., Castracani, C. C., et al. (2020) · Metabolites · doi:10.3390/metabo10100391 · Cited by 54

Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators

Bruen, R., Curley, S., Kajani, S., Lynch, G. M., O'Reilly, M. E., Dillon, E., Brennan, E. P., Barry, M. C., Sheehan, S. J., McGillicuddy, F. C., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258343 · Cited by 55

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study

Rizvi, A. A., Patti, A. M., Giglio, R. V., Nikolić, D., Amato, A., Busaidi, N. A., Al‐Rasadi, K., Soresi, M., Banach, M., Montalto, G., et al. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1067299 · Cited by 52

Ferroptosis: mechanism and role in diabetes-related cardiovascular diseases

Wang, Z., Wu, C., Yin, D., & Dou, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02614-x · Cited by 53

The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health

Qassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 61

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice

von Scholten, B. J., Kreiner, F. F., Rasmussen, S., Rossing, P. R., & Idorn, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221112490 · Cited by 41

Liraglutide activates autophagyviaGLP-1R to improve functional recovery after spinal cord injury

Chen, J., Wang, Z., Mao, Y., Zheng, Z., Chen, Y., Khor, S., Shi, K., He, Z., Li, J., Gong, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20791 · Cited by 40

Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease

Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 36

Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials

Patoulias, D., Popovic, D. S., Stoian, A. P., Janež, A., Sahebkar, A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108529 · Cited by 38

Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis

Hiramatsu, T., Ozeki, A., Asai, K., Saka, M., Hobo, A., & Furuta, S. (2015) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12319 · Cited by 34

Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

Alasmari, A. F., Ali, N., Alasmari, F. F., Alanazi, W. A., Alshammari, M. A., Al-Harbi, N. O., Alhoshani, A., Sobeai, H. M. A., Alswayyed, M., Alanazi, M. M., et al. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.03.002 · Cited by 34

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes

Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 35

Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot

Vujčić, S., Kotur‐Stevuljević, J., Vekić, J., Perović-Blagojević, I., Stefanović, T., Ilić-Mijailović, S., Uzelac, B. K., Bosić, S., Antonić, T., Guzonjić, A., et al. (2022) · Medicina · doi:10.3390/medicina58121866 · Cited by 36

Liraglutide Promotes the Osteogenic Differentiation in MC3T3-E1 Cells via Regulating the Expression of Smad2/3 Through PI3K/Akt and Wnt/β-Catenin Pathways

Gao, L., Li, S., & Li, Y. (2018) · DNA and Cell Biology · doi:10.1089/dna.2018.4397 · Cited by 33

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies

Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 35

Cardiovascular Effects of the New Weight Loss Agents

Vorsanger, M., Subramanyam, P., WEINTRAUB, H. S., Lamm, S. H., Underberg, J. A., Gianos, E., Goldberg, I. J., & Schwartzbard, A. Z. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.007 · Cited by 33

Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus

Fan, M., Li, Y., & Zhang, S. (2016) · Medicine · doi:10.1097/md.0000000000002386 · Cited by 31

Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials

Salamah, H. M., Marey, A., Abugdida, M., Abualkhair, K. A., Elshenawy, S., Elhassan, W. A. F., Naguib, M. M., Malnev, D., Durrani, J., Bailey, R., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01371-3 · Cited by 36

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 32

Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials

Jakhar, D. K., Vishwakarma, V. K., Singh, R., Jadhav, K., Shah, S. Z., Arora, T. K., Verma, R. K., & Yadav, H. N. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122585 · Cited by 30

Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: From fundamental research to therapy

Zhang, X., Han, X.-W., Jiang, Y., Wang, Y., He, X.-L., Liu, D., Huang, J., Liu, H.-H., Ye, T., Li, S.-J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110747 · Cited by 29

Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review

Mahé, G., Aboyans, V., Cosson, E., Mohammedi, K., Sarlon-Bartoli, G., Lanéelle, D., Mirault, T., & Darmon, P. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02325-9 · Cited by 32

Heme oxygenase, biliverdin reductase, and bilirubin pathways regulate oxidative stress and insulin resistance: a focus on diabetes and therapeutics

Lee, W., Kipp, Z. A., Pauss, S. N., Martinez, G. J., Bates, E. A., Badmus, O. O., Stec, D. E., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20242825 · Cited by 30

Liraglutide relieves cardiac dilated function than DPP ‐4 inhibitors

Hiramatsu, T., Asano, Y., Mabuchi, M., Imai, K., Iguchi, D., & Furuta, S. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13007 · Cited by 28

Plasma heme oxygenase-1 is decreased in peripheral artery disease patients

Signorelli, S. S., Volsi, G. L., Fiore, V., Mangiafico, M., Barbagallo, I. A., Parenti, R., Rizzo, M., & Volti, G. L. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5644 · Cited by 27

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome

Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 33

Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes

Garg, M., Ghanim, H., Kuhadiya, N. D., Green, K., HEJNA, J. M., Abuaysheh, S., Torre, B., Batra, M., Makdissi, A., Chaudhuri, A., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12944 · Cited by 26

Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes

Tanaka, K., Saisho, Y., Kawai, T., Tanaka, M., Meguro, S., Irie, J., Imai, T., Shigihara, T., Morimoto, J., Yajima, K., et al. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej14-0602 · Cited by 26

Liraglutide, a TFEB‐Mediated Autophagy Agonist, Promotes the Viability of Random‐Pattern Skin Flaps

Zhu, X., Hu, X., Lou, J., Li, J., Xu, Y. M., Yu, G., Wu, C., Ding, J. H., Gao, W., Xiao, J., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6610603 · Cited by 25

Targeting NRF2 in Type 2 diabetes mellitus and depression: Efficacy of natural and synthetic compounds

Subba, R., Ahmad, M. H., Ghosh, B., & Mondal, A. C. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174993 · Cited by 26

Liraglutide, a glucagon‑like peptide‑1 analog, inhibits high glucose‑induced oxidative stress and apoptosis in neonatal rat cardiomyocytes

Zhang, L., Li, C., Zhu, Q., Li, N., & Zhou, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7388 · Cited by 26

The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K/p-Akt/GSK3-β/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB/BDNF/TrkB cascade

Hassan, N. F., Ragab, D., Ibrahim, S. G., Elgalil, M. M. A., Abd-El-Hamid, A. H., Hamed, D. M., William, M. M., & Salem, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112308 · Cited by 24

Antioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms

Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9959320 · Cited by 26

Diabetes and Vascular Disease: Is It All About Glycemia?

Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 23

Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system

Li, L.-Q., Yao, M.-Y., Ma, J.-X., Xue, P., & Li, Y.-K. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0016 · Cited by 20

Incretins and microRNAs: Interactions and physiological relevance

Radbakhsh, S., Sathyapalan, T., Banach, M., & Sahebkar, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104662 · Cited by 20

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes

Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 22

Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes

Wu, Z., Deng, W., Ye, Y., Xu, J., Han, D., Zheng, Y., & Zheng, Q. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1378291 · Cited by 19

Activation of pCREB/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI)

Abdelaziz, A. I., Mantawy, E. M., Gad, A. M., Fawzy, H. M., & Azab, S. S. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110719 · Cited by 19

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review

Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Rizvi, A. A., Janež, A., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01170-3 · Cited by 18

Molecular Basis of Cardiomyopathies in Type 2 Diabetes

Giardinelli, S., Meliota, G., Mentino, D., D’Amato, G., & Faienza, M. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158280 · Cited by 18

Perinatal Oxidative Stress May Affect Fetal Ghrelin Levels in Humans

Luo, Z., Bilodeau, J., Nuyt, A. M., Fraser, W. D., Julien, P., Audibert, F., Xiao, L., Garofalo, C., & Levy, E. H. (2015) · Scientific Reports · doi:10.1038/srep17881 · Cited by 16

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL

Idzerda, N. M. A., Clegg, L. E., Hernandez, A. F., Bakris, G. L., Penland, R. C., Boulton, D. W., Bethel, M. A., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13958 · Cited by 15

Incretin and glucagon receptor polypharmacology in chronic kidney disease

McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17

Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence

Mooradian, A. D. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0199-7 · Cited by 15

Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity

Terenzi, D. C., Bakbak, E., Teoh, H., Krishnaraj, A., Puar, P., Rotstein, O. D., Cosentino, F., Goldenberg, R., Verma, S., & Hess, D. C. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvae016 · Cited by 14

Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study

Yao, M., Li, L., Ma, J., Xue, P., & Li, Y. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198652 · Cited by 13

Antioxidant enzymes and vascular diseases

Radovanović, J., Banjac, K., Obradovic, M. M., & Isenović, E. R. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00070 · Cited by 14

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment

Hiramatsu, T., Ito, H., Okumura, S., Asano, Y., Iguchi, D., & Furuta, S. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120971220 · Cited by 12

Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study

Hiramatsu, T., Ozeki, A., Ishikawa, H., & Furuta, S. (2017) · Drug Research · doi:10.1055/s-0043-110603 · Cited by 11

Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?

Katsiki, N., Christou, G. A., & Kiortsis, D. N. (2015) · Current Vascular Pharmacology · doi:10.2174/157016111401151126161741 · Cited by 11

Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia

Alnaser, R. I., Alassaf, F. A., & Abed, M. N. (2024) · Journal of Bone Metabolism · doi:10.11005/jbm.24.739 · Cited by 12

Association of the microsatellite (GT)n repeat polymorphisms of the HO-1 gene promoter and corresponding serum levels with the risk of laryngeal squamous cell carcinoma

Tang, D., Tang, W.-J., Shi, X., Li, W., Zhou, H. K., Lu, L., & Tao, L. (2016) · Acta Oto-Laryngologica · doi:10.3109/00016489.2016.1157265 · Cited by 10

Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication

Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., Takeda, H., Yokomizo, H., et al. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231222837 · Cited by 9

Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs – The CAPISCO International Expert Panel

Popovic, D. S., Παπάνας, Ν., Koufakis, T., Kotsa, K., Almahmeed, W. A., Al‐Rasadi, K., Al-Alawi, K., Banach, M., Banerjee, Y., Ceriello, A., et al. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2019-1111 · Cited by 8

Antinociceptive Behavior, Glutamine/Glutamate, and Neopterin in Early-Stage Streptozotocin-Induced Diabetic Neuropathy in Liraglutide-Treated Mice under a Standard or Enriched Environment

Andreeva-Gateva, P. A., Hristov, M., Ivanova, N. M., Vasileva, D., Ivanova, A., Sabit, Z., Bogdanov, T. G., Apostolova, S. N., & Tzoneva, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910786 · Cited by 8

The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes

Ceriello, A., Nigris, V. D., Pujadas, G., Sala, L. L., Bonfigli, A. R., Testa, R., Uccellatore, A., & Genovese, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.019 · Cited by 8

Serum bilirubin levels are positively associated with glycemic variability in women with type 2 diabetes

Kim, L.-K., Roh, E., Kim, M. J., Kim, M. K., Park, K. S., Kwak, S. H., Cho, Y. M., Park, K. S., Jang, H. C., & Jung, H. S. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12529 · Cited by 7

Very low‐calorie ketogenic diet and liraglutide as a synergistic strategy for the treatment of obesity: A short‐term, non‐randomised, observational, real‐world clinical evaluation

Camajani, E., Masi, D., Spizzichini, M. L., Cori, C., Rossetti, R., Spoltore, M. E., Tuccinardi, D., Lubrano, C., Gnessi, L., Isidori, A. M., et al. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16658 · Cited by 7

Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy

Ninčević, V., Zjalić, M., Kolarić, T. O., Smolić, M., Kizivat, T., Kuna, L., Včev, A., Tabll, A. A., & Bilić-Čurčić, I. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44030072 · Cited by 7

Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs

Kim, H. J., Kim, S. S., & Song, S. H. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.515 · Cited by 7

Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1–Infected Patients

Taylor, N., Kremser, I., Auer, S., Hoermann, G., Greil, R., Haschke‐Becher, E., Esterbauer, H., Kenner, L., & Oberkofler, H. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001223 · Cited by 6

GLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes

Srivastava, S., Pandey, H. K., Singh, S. K., & Tripathi, Y. B. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.039 · Cited by 6

Cardiovascular effects of glucagon‐like peptide‐1 receptor agonist therapies in patients with type 1 diabetes

Rizzo, M., Rizvi, A. A., & Sesti, G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12883 · Cited by 6

Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide

Masood, A., Benabdelkamel, H., Joy, S. S., Alhossan, A., Alsuwayni, B. M., Abdeen, G. N., Aldhwayan, M., Alfadda, N. A., Miras, A. D., & Alfadda, A. A. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1458675 · Cited by 5

GLP-1 receptor agonists, carotid atherosclerosis and retinopathy

Rizzo, M., Nikolić, D., Pace, F. D., Παπάνας, Ν., & Montano, N. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1342810 · Cited by 5

Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin

Mayyas, F., & Omeish, A. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123721 · Cited by 4

Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus

Abdel‐Aal, R. A., Hareedy, M. S., Badary, D. M., Abdelnabi, S., & Hussein, A. M. R. (2025) · Drug Development Research · doi:10.1002/ddr.70160 · Cited by 4

Novel approaches to pharmacological management of type 2 diabetes in Japan

Kaneko, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1974401 · Cited by 5

New antihyperglycaemic agents and cardiovascular disease

Pafili, K., Rizzo, M., & Παπάνας, Ν. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000524 · Cited by 4

Impact of different hormones on the regulation of nitric oxide in diabetes

Gluvic, Z. M., Obradovic, M. M., Manojlovic, M. S., Giglio, R. V., Patti, A. M., Ciaccio, M., Suri, J. S., Rizzo, M., & Isenović, E. R. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112325 · Cited by 3

Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists

Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3

Liraglutide limits the immunogenic cell death-mediated ROS propagation and PI3K/AKT inactivation after doxorubicin-induced gonadotoxicity in rats: Involvement of the canonical Hedgehog trajectory

Zaky, D. A., Sayed, R. H., & Mohamed, Y. S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110212 · Cited by 3

Microvascular and macrovascular effects of liraglutide

Cianflone, D., Rizvi, A. A., & Rizzo, M. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.041 · Cited by 3

Effects of liraglutide on plasma ghrelin concentrations and oxidative stress in patients with type 2 diabetes: a 2-month prospective pilot study.

Volti, G. L., Patti, A. L., Barbagallo, I. A., Bartolo, V. D., Giglio, R. V., Tamburello, A., Zabbara, A., & Abate, N. (2012) · Diabetologia · Cited by 1

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

Sivalingam, S., Larsen, E. L., van Raalte, D. H., Muskiet, M. H. A., Smits, M. M., Tonneijck, L., Joles, J. A., von Scholten, B. J., Zobel, E. H., Persson, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90191-w · Cited by 23

Effect of liraglutide combined with basal insulin on blood glucose control, lipid metabolism and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus complicated by obesity

He, F.-F., Song, M.-X., & Xu, L. (2018) · DOAJ (DOAJ: Directory of Open Access Journals)

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study

Nagaike, H., Ohara, M., Kohata, Y., Hiromura, M., Tomoyasu, M., Takada, M., Yamamoto, T., Hayashi, T., Fukui, T., & Hirano, T. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0560-8 · Cited by 26

The effect of one year treatment with GLP1-RA, SGLT2i and their combination on plasma levels of oxidative and antioxidative biomarkers

Ikonomidis, I., Thymis, J., Pavlidis, G., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Korakas, E., Kostelli, G., Triantafyllou, C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab724.2959